Table 2.
Primary, secondary, and economic outcome measures
| GPD-CBT (n=68) | SFBT (n=68) | ||
|---|---|---|---|
| Dichotomous measures of outcome | |||
| CGI-I much or very much improved | |||
| After treatment | 40 (59%) | 47 (69%) | |
| 6 month follow-up | 45 (66%) | 49 (72%) | |
| Free of primary anxiety disorder diagnosis | |||
| After treatment | 33 (50%) | 40 (59%) | |
| 6 month follow-up | 47 (69%) | 46 (68%) | |
| Free of all anxiety disorder diagnoses | |||
| After treatment | 25 (37%) | 30 (44%) | |
| 6 month follow-up | 34 (50%) | 35 (51%) | |
| Continuous measures of outcome | |||
| ADIS-c/p clinical severity rating of primary diagnosis* | |||
| Baseline | 5·10 (1·08); n=68 | 5·13 (1·02); n=68 | |
| After treatment | 2·60 (2·00); n=55 | 2·77 (1·94); n=65 | |
| 6 month follow-up | 1·88 (1·90); n=56 | 1·89 (1·96); n=62 | |
| SCAS-c* | |||
| Baseline | 38·61 (20·31); n=54 | 34·15 (20·06); n=60 | |
| After treatment | 31·49 (24·09); n=45 | 24·36 (18·28); n=59 | |
| 6 month follow-up | 23·77 (18·96); n=44 | 19·55 (17·08); n=55 | |
| SCAS-p* | |||
| Baseline | 35·41 (17·55); n=66 | 32·56 (13·54); n=66 | |
| After treatment | 24·76 (12·88); n=51 | 24·44 (13·61); n=62 | |
| 6 month follow-up | 22·41 (11·58); n=51 | 23.05 (14.67); n=58 | |
| CAIS-c (25 items)* | |||
| Baseline | 15·95 (11·89); n=55 | 16·85 (11·44); n=62 | |
| After treatment | 10·55 (12·02); n=44 | 10·39 (9·80); n=59 | |
| 6 month follow-up | 9·68 (13·56); n=41 | 7·88 (7·90); n=52 | |
| CAIS-p (25 items)* | |||
| Baseline | 20·43 (12·24); n=64 | 19·90 (11·47); n=62 | |
| After treatment | 13·59 (12·41); n=51 | 12·04 (9·91); n=57 | |
| 6 month follow-up | 10·84 (11·79); n=49 | 12·27 (10·93); n=55 | |
| KFQ-c* | |||
| Baseline | 59·93 (11·33); n=68 | 58·68 (12·04); n=68 | |
| After treatment | 52·96 (14·22); n=50 | 51·56 (13·17); n=62 | |
| 6 month follow-up | 50·23 (11·75); n=47 | 47·40 (12·94); n=58 | |
| CHU-9D-c† | |||
| Baseline | 0·87 (0·09); n=64 | 0·88 (0·09); n=65 | |
| After treatment | 0·90 (0·10); n=49 | 0·90 (0·09); n=59 | |
| 6 month follow-up | 0·91 (0·08); n=47 | 0·91 (0·08); n=55 | |
| CHU-9D-p† | |||
| Baseline | 0·85 (0·10); n=46 | 0·89 (0·07); n=54 | |
| After treatment | 0·92 (0·07); n=53 | 0·92 (0·07); n=53 | |
| 6 month follow-up | 0·93 (0·07); n=48 | 0·92 (0·07); n=56 | |
| EQ-5D-Y-c† | |||
| Baseline | 0·82 (0·15); n=63 | 0·80 (0·20); n=67 | |
| After treatment | 0·88 (0·21); n=48 | 0·86 (0·21); n=61 | |
| 6 month follow-up | 0·87 (0·19); n=47 | 0·91 (0·16); n=57 | |
Data are n (%) or mean (SD); n. GPD-CBT=guided parent-delivered-cognitive behavioural therapy. SFBT=solution-focused brief therapy. CGI-I=Clinician Global Impression-Improvement. ADIS-c/p=Anxiety Disorders Interview Schedule for DSM-IV child and parent version. SCAS-c=Spence Children's Anxiety Scale-child report. SCAS-p=Spence Child Anxiety Scale-parent report. CAIS-c=Child Anxiety Impact Scale-child report. CAIS-p=Child Anxiety Impact Scale-parent report. KFQ-c=Koala Fear Questionnaire-child report. CHU-9D-c=Child Health Utility-9D-child report. CHU-9D-p=Child Health Utility-9D-parent report. EQ-5D-Y=EuroQol-5D-Youth version-child report.
A higher score indicates higher symptoms or severity.
A higher score indicates higher quality of life.